A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab
NCT07532213 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2026-04-15
Summary
The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.
Conditions
- Inflammatory Bowel Disease
- Colitis, Ulcerative
- Crohn Disease
Sponsors & Collaborators
-
Janssen-Cilag A.G., Switzerland
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-23
- Primary Completion
- 2029-04-10
- Completion
- 2029-04-10
More Related Trials
-
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232 ·Status: RECRUITING ·Phase: PHASE3
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT04397263 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
NCT07528040 ·Status: NOT_YET_RECRUITING
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study
NCT07034664 ·Status: RECRUITING
-
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073 ·Status: RECRUITING ·Phase: PHASE3
-
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
NCT07444060 ·Status: RECRUITING
-
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
NCT03606499 ·Status: COMPLETED
-
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
NCT01369329 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
NCT04372108 ·Status: RECRUITING
-
Safety and Efficiency of the Universal CNK-UT009 in Difficult-to-treat Inflammatory Bowel Disease Patients
NCT07416383 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
NCT05029921 ·Status: COMPLETED ·Phase: PHASE4
-
Predictive Factors of Clinical Response to Ustekinumab in Active Crohn's Disease
NCT03351647 ·Status: COMPLETED
-
Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis,
NCT07529236 ·Status: NOT_YET_RECRUITING
-
Long-term Treatment With Ustekinumab in Patients With Crohn's Disease and Ulcerative Colitis: a Cohort Study
NCT06802887 ·Status: RECRUITING
-
Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.
NCT06912815 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis
NCT03358706 ·Status: TERMINATED ·Phase: PHASE1
-
Prognosis in UC After First Biological
NCT05530122 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
NCT01369342 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
NCT00265122 ·Status: COMPLETED ·Phase: PHASE2